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Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S159GVHD prophylaxis consisted of the continuous infusion of
tacrolimus, 1 mg/kg/day of methylprednisolone, and 15 mg/
kg/day ofMMF. PBSC containing 1.78-8.46 * 10e6/kg of CD34+
cells were transplanted in all cases.
Findings & Interpretation: Granulocyte engraftment was
achieved on days 9-11 in all cases. Complete spousal chi-
merism in PB was conﬁrmed on days 3-13 by STR-PCR.
Acute GVHD was controllable except in the rejection case,
who died of grade IV GVHD on day 39. All ﬁve relapse
cases achieved complete remission once, and three could
be discharged. One patient died of VOD/SOS on day 62, and
one patient was transferred to her local hospital. The
remaining four patients excluding GVHD and VOD/SOS
cases ﬁnally developed disease relapse (in BM 2, CNS 2) on
days 106-334, and died as a direct result on days 152-548.
Discussion & Implications: Since these cases are refractory
and they received their third SCT, we cannot refer to the
GVL effect, and GVHD would be acceptable in spousal SCT.
The immune recovery remains to be elucidated over a
long-term follow-up.192
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In a pilot study, we carried out Haploidentical trans-
plantation for 10 patients with severe aplastic anemia (SAA)
using peripheral blood stem cell (PBSC) graft and post-
transplantation cyclophosphamide (PTCY). The conditioning
comprised of Fludarabine 150 mg/m2, CY 30 mg/kg, horse
ATG 45 mg/kg and Melphalan 120 mg/m2, followed by PTCY
50 mg /kg on D+3, +4 and cyclosporine and mycophenolate
from D + 5. Prompt engraftment was followed by early
alloreactivity, resulting in transplant-relatedmortality in 4 of
the ﬁrst 5 patients, all with NK Ligandmismatched donors. In
the subsequent 5 patients, Sirolimus was introduced from
Day -7 to maintain a trough level of 8-14 ng/ml on the day of
transplant and was continued for 12months post-transplant,
with a reduced trough level for cyclosporine. All 5 patients
had prompt engraftment with 78-100% donor chimerism
and mild chronic GVHD in one patient only. The only sig-
niﬁcant toxicity observed in these patients was Sirolimus
associated acneform lesions. Analysis of Regulatory T cells at
45 days posttransplant was 0.09  0.13% in the ﬁrst 3/5 pa-
tients compared to 2.6  0.77% in those receiving Sirolimus
(p¼0.001). Our study demonstrates that NK cell ligand mis-
matched donors are associated with early alloreactivity
following Haploidentical PBSC transplantation for SAA but
addition of Sirolimus to PTCY improves tolerance and out-
come.193
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Background: Almost 1% of the Japanese population has HLA-
homozygous haplotypes (the same HLA haplotypes). An HLA
mismatch between patients with HLA-homozygous haplo-
types and their children or parents is absent in the graft-
versus-host (GVH) direction. Hematopoietic stem cell
transplantation (SCT) from a haploidentical donor with HLA
mismatch only in the host-versus-graft (HVG) direction was
feasible using standard GVHD prophylaxis (Ikegame K, et al.
IJH 2012). However, this should be validated in a larger
cohort.
Methods: We analyzed 229 patients with hematologic ma-
lignancies who had homozygous HLA-A, -B, and -DR antigens
and received their ﬁrst allogeneic SCT from a related donor
without an HLA mismatch in the GVH direction between
1998 and 2012 in Japan. In total, 155 patients received SCT
from an HLA-matched related donor (homo-to-homo SCT)
and 74 received SCT from a haploidentical donor with HLA
mismatch only in the HVG direction (hetero-to-homo SCT).
High-risk disease and the use of tacrolimus were more
frequently observed in the hetero-to-homo SCT group. The
number of HLA mismatches in the HVG direction was 1 in 16
patients, 2 in 27 patients, and 3 in 31 patients. The impact of
hetero-to-homo versus homo-to-homo SCT was analyzed
after adjusting for transplant year, age, and other signiﬁcant
variables.
Results: There was no signiﬁcant difference in the cumu-
lative incidence of neutrophil engraftment and severe
acute GVHD between the hetero-to-homo and homo-to-
homo SCT groups (neutrophil engraftment at 50 days, 91%
vs. 95%; adjusted hazard ratio (aHR) 1.05, P ¼ 0.768; se-
vere acute GVHD at 100 days, 10% vs. 5%; aHR 1.68, P ¼
0.320). Non-relapse mortality was signiﬁcantly higher in
the hetero-to-homo SCT group than in the homo-to-homo
SCT group (26% vs. 10% at 5 years; aHR 2.42, P ¼ 0.013),
whereas there was no signiﬁcant difference in the relapse
rate. This resulted in non-signiﬁcant lower overall survival
in the hetero-to-homo SCT group (35% vs. 57% at 5 years;
aHR 1.41, P ¼ 0.083).
Conclusions: Hetero-to-homo SCT is usually considered
only when transplantation should be performed immedi-
ately for high-risk disease. Therefore, differences in patient
background between the homo-to-homo and hetero-to-
homo SCT groups may have biased the comparison. How-
ever, it should be noted that there was no signiﬁcant
difference in neutrophil engraftment as well as severe acute
GVHD. Although non-relapse mortality and overall mortal-
ity rates were higher in the hetero-to-homo SCT group than
